Equities Analysts Offer Predictions for Accuray Incorporated’s FY2022 Earnings (NASDAQ:ARAY)

Accuray Incorporated (NASDAQ:ARAYGet Rating) – Research analysts at Jefferies Financial Group increased their FY2022 earnings estimates for shares of Accuray in a note issued to investors on Wednesday, April 27th. Jefferies Financial Group analyst F. Pinal now expects that the medical equipment provider will earn ($0.07) per share for the year, up from their prior estimate of ($0.11). Jefferies Financial Group also issued estimates for Accuray’s Q4 2022 earnings at ($0.05) EPS.

Several other equities research analysts have also recently weighed in on ARAY. TheStreet cut shares of Accuray from a “c-” rating to a “d” rating in a research report on Thursday. StockNews.com raised shares of Accuray from a “hold” rating to a “buy” rating in a research report on Thursday.

Accuray stock opened at $2.66 on Monday. The firm has a 50-day moving average of $3.30 and a two-hundred day moving average of $4.15. Accuray has a 1 year low of $2.66 and a 1 year high of $5.93. The stock has a market cap of $246.67 million, a price-to-earnings ratio of -19.00 and a beta of 1.91. The company has a debt-to-equity ratio of 3.42, a current ratio of 1.72 and a quick ratio of 1.11.

Accuray (NASDAQ:ARAYGet Rating) last released its quarterly earnings data on Wednesday, April 27th. The medical equipment provider reported ($0.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.04) by $0.03. Accuray had a negative net margin of 3.01% and a negative return on equity of 5.59%.

In related news, VP Michael Hoge sold 11,653 shares of the business’s stock in a transaction that occurred on Tuesday, March 1st. The shares were sold at an average price of $3.43, for a total transaction of $39,969.79. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 4.00% of the stock is currently owned by corporate insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of ARAY. Covestor Ltd bought a new position in shares of Accuray during the 4th quarter worth approximately $41,000. Point72 Hong Kong Ltd increased its stake in Accuray by 195.1% during the 4th quarter. Point72 Hong Kong Ltd now owns 10,431 shares of the medical equipment provider’s stock valued at $50,000 after purchasing an additional 6,896 shares in the last quarter. Bowling Portfolio Management LLC acquired a new position in Accuray during the 1st quarter valued at approximately $51,000. Ilmarinen Mutual Pension Insurance Co acquired a new position in Accuray during the 4th quarter valued at approximately $54,000. Finally, LPL Financial LLC purchased a new stake in shares of Accuray in the 4th quarter valued at $57,000. Hedge funds and other institutional investors own 70.43% of the company’s stock.

About Accuray (Get Rating)

Accuray Incorporated develops, manufactures, and sells radiotherapy systems for alternative cancer treatments in the Americas, Europe, the Middle East, India, Africa, Japan, China, and rest of the Asia Pacific region. It offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body, such as prostate, lung, brain, spine, liver, pancreas, and kidney.

See Also

Earnings History and Estimates for Accuray (NASDAQ:ARAY)

Receive News & Ratings for Accuray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray and related companies with MarketBeat.com's FREE daily email newsletter.